Core Viewpoint - CalciMedica, Inc. has announced a public offering of 2,720,000 shares at $3.75 per share, aiming to raise approximately $10.2 million before expenses [1]. Company Overview - CalciMedica is a clinical-stage biopharmaceutical company focused on developing CRAC channel inhibition therapies for inflammatory and immunologic diseases [5]. - The company's lead product candidate, Auxora™, has shown positive results in multiple clinical trials, including a Phase 2b trial for acute pancreatitis and a Phase 2 trial for COVID pneumonia [5]. - CalciMedica is currently conducting a Phase 2 trial for acute kidney injury and supporting an ongoing Phase 1/2 trial for acute inflammatory pulmonary thrombosis, with data expected in 2025 [5]. Offering Details - The public offering consists of 2,720,000 shares priced at $3.75 each, with gross proceeds expected to be $10,200,000 [1]. - The underwriters have a 30-day option to purchase an additional 408,000 shares at the same price [1]. - The offering is expected to close around November 1, 2024, pending customary closing conditions [1]. Regulatory Information - The offering is made under a shelf registration statement filed with the SEC, which was declared effective on August 18, 2023 [3]. - A preliminary prospectus supplement was filed on October 30, 2024, with a final prospectus supplement to be made available on the SEC's website [3].
CalciMedica Announces Pricing of Public Offering of Common Stock